Literature DB >> 22890

Does dopamine play a role in schizophrenia?

A Carlsson.   

Abstract

Inhibition of central dopamine functions appears to be a common basic property of antipsychotic drugs. The mesolimbic and nigrostriatal portions of the dopaminergic system are probably the main targets of these drugs for the mental and the extrapyramidal actions respectively. Dopaminergic hyperfunction, induced by amphetamines or dopa, may lead to a disturbance mimicking paranoid schizophrenia, lending further support for a key role of dopamine in mental functions. While a primary disturbance in dopamine function in schizophrenia cannot be ruled out, the intimate relationship between dopaminergic and other neuronal systems must be emphasized. The possible involvement of other amine, aminoacid or peptide transmitters in schizophrenia cannot be disregarded.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 22890     DOI: 10.1017/s003329170000622x

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  33 in total

Review 1.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

2.  Negative symptoms and the failure to represent the expected reward value of actions: behavioral and computational modeling evidence.

Authors:  James M Gold; James A Waltz; Tatyana M Matveeva; Zuzana Kasanova; Gregory P Strauss; Ellen S Herbener; Anne G E Collins; Michael J Frank
Journal:  Arch Gen Psychiatry       Date:  2012-02

Review 3.  Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse.

Authors:  Matcheri S Keshavan; Henry A Nasrallah; Rajiv Tandon
Journal:  Schizophr Res       Date:  2011-02-12       Impact factor: 4.939

4.  Oxytocin in schizophrenia: a review of evidence for its therapeutic effects.

Authors:  Kai Macdonald; David Feifel
Journal:  Acta Neuropsychiatr       Date:  2011-12-19       Impact factor: 3.403

Review 5.  Drug-induced akathisia: a review.

Authors:  R Ball
Journal:  J R Soc Med       Date:  1985-09       Impact factor: 5.344

Review 6.  Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder.

Authors:  C Mehler-Wex; P Riederer; M Gerlach
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

7.  Lithium does not interact with haloperidol in the dopaminergic pathways of the rat brain.

Authors:  A Reches; V Jackson-Lewis; S Fahn
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  Arvid Carlsson, and the story of dopamine.

Authors:  Vikram K Yeragani; Manuel Tancer; Pratap Chokka; Glen B Baker
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

9.  Tolerance to fluphenazine and supersensitivity to apomorphine in central dopaminergic systems after chronic fluphenazine decanoate treatment.

Authors:  S C Wheeler; R H Roth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-06       Impact factor: 3.000

Review 10.  Recent advances in treating cognitive impairment in schizophrenia.

Authors:  Cherrie Galletly
Journal:  Psychopharmacology (Berl)       Date:  2008-09-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.